---
title: "Daré Bioscience posts Phase 1 data showing topical sildenafil cream well tolerated in postmenopausal women"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297047748.md"
description: "Daré Bioscience published Phase 1 data for its topical sildenafil cream in postmenopausal women, showing it was well-tolerated with limited systemic exposure compared to oral sildenafil. The study supports localized delivery to improve genital arousal while reducing side effects. Prescription dispensing for the 503B compounded version is expected to begin in Q3 2026 as FDA pathway work continues."
datetime: "2026-08-26T12:45:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297047748.md)
  - [en](https://longbridge.com/en/news/297047748.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297047748.md)
generator: "portal-rs"
---

# Daré Bioscience posts Phase 1 data showing topical sildenafil cream well tolerated in postmenopausal women

-   Daré Bioscience disclosed publication of Phase 1 results for its topical sildenafil cream in healthy postmenopausal women. \* Results were already presented via a peer-reviewed journal publication, not flagged for a future medical meeting. \* Study showed the cream was well tolerated, with limited drug exposure in the bloodstream versus oral sildenafil. \* Data supported localized delivery aimed at improving genital arousal while reducing systemic side effects. \* Prescription dispensing for the 503B compounded version is expected to start in Q3 2026 as FDA-pathway work continues. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608260845PRIMZONEFULLFEED9816127) on August 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [DARE.US](https://longbridge.com/en/quote/DARE.US.md)

## Related News & Research

- [Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript](https://longbridge.com/en/news/295850563.md)
- [Dare Slides on MyMenopauseRx Hookup](https://longbridge.com/en/news/294084614.md)
- [China Medical System wins China approval for ruxolitinib cream in atopic dermatitis](https://longbridge.com/en/news/297894031.md)
- [Rush Enterprises, MCT Companies complete 50-50 joint venture in Carrier Transicold dealer network](https://longbridge.com/en/news/298071396.md)
- [Bristol-Myers Squibb (BMY) Following Camzyos Data And Zola Cel Pause Still Looks Fully Valued](https://longbridge.com/en/news/298117403.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**